Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mimran, A.
Right arrow Articles by Monnier, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mimran, A.
Right arrow Articles by Monnier, L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 11, Issue 10 850-853, Copyright © 1988 by American Diabetes Association

ARTICLES

Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy

A Mimran, A Insua, J Ribstein, J Bringer and L Monnier
Department of Medicine, Centre Hospitalier Universitaire, Montpellier, France.

In these studies, the effect of a 6-wk treatment by placebo, the calcium-channel blocker nifedipine, or the converting-enzyme inhibitor captopril was assessed in normotensive patients with insulin-dependent diabetes and incipient nephropathy. In response to captopril and nifedipine, arterial pressure decreased slightly and to a similar extent. These drugs resulted in opposite effects on urinary excretion of albumin [i.e., increase in urinary albumin excretion (UAE) by 40% during nifedipine treatment and decrease by 40% during captopril treatment]. No change in UAE was observed in the placebo group. This observation of opposite changes in UAE in the presence of a similar fall in arterial pressure suggests that the effects of captopril and nifedipine on UAE result from some difference in their intrarenal action. The data do not present recommendations for the use or disuse of captopril or nifedipine in such a group of patients and do not allow extrapolation to hypertensive diabetic subjects well controlled by other conventional antihypertensive agents.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
N. Khosla and G. Bakris
Lessons Learned from Recent Hypertension Trials about Kidney Disease
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 229 - 235.
[Full Text] [PDF]

Home page
 JAMAHome page
L. Y. Agodoa, L. Appel, G. L. Bakris, G. Beck, J. Bourgoignie, J. P. Briggs, J. Charleston, D. Cheek, W. Cleveland, J. G. Douglas, et al.
Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial
JAMA, June 6, 2001; 285(21): 2719 - 2728.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Bojestig, B. E. Karlberg, T. Lindström, and F. H. Nystrom
Reduction of ACE Activity Is Insufficient to Decrease Microalbuminuria in Normotensive Patients With Type 1 Diabetes
Diabetes Care, May 1, 2001; 24(5): 919 - 924.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1988 by the American Diabetes Association.